

nanoTherics Limited

(“nanoTherics” or “the Company”)

nanoTherics Launches the **magneTherm™** - The Only Commercially Available Hyperthermia Device With Frequency Selection

nanoTherics, a scientific medical research devices company founded in 2007, is pleased to announce launch of the magneTherm™, a new device designed to measure thermal effects of magnetic nanoparticles for hyperthermia applications. The system is totally unique and is the only commercially available hyperthermia device available for measuring these thermal effects that includes flexibility in frequency selection.

nanoTherics's primary business is supply of improved scientific devices and associated products to research laboratories in the pharmaceutical and biotechnology industries as well as academia. The Company's main products follow from >30 years combined cutting edge research into magnetic nanoparticle use conducted at Keele University and University of Florida and apply a patent-pending technology using nanoparticles and magnetic fields to facilitate enhanced delivery of biomolecules, such as DNA, into living cells.

Dr Linda Cammish, Chief Executive Officer, said, “We are delighted to launch the magneTherm”. She added, “It follows our March 2009 launch of the magneFect-nano which uses proprietary oscillating magnetic arrays to promote particle/DNA uptake into cells to improve gene transfection whilst maintaining cell viability. The introduction of these systems is illustrative of our expertise in magnetic nanoparticle technology for a range of life science research and human health applications, in the emerging field of nanomedicine arena and shows our commitment to product development to meet customer's needs.”

Notes for editors

About nanoTherics

nanoTherics Ltd was formed in August 2007 to exploit a novel gene transfection technology arising from biomedical research conducted at Keele University and the University of Florida. The patented technology uses nanoparticles and magnetic fields to facilitate improved delivery of foreign molecules, including DNA, into living cells. nanoTherics's gene transfection studies have shown significant performance enhancement over the best non-viral techniques currently on the market, demonstrating high levels of transfection whilst maintaining viability of transfected cells. These key attributes afford a significant competitive advantage over currently available systems.

nanoTherics's mission is to position its novel gene transfection technology as the new "gold standard" for transfection, underpinning research and development of current and future gene therapy programmes.

For more information go to www.nanotherics.com

Contact: Dr Linda E Cammish, CEO: email: linda@nanotherics.com; Tel: 07981 112968

Photo:

